Aandeel 603739 QINGDAO VLAND BIOTECH INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Qingdao Vland Biotech INC.

Aandelen

603739

CNE100003GX8

slotkoers Shanghai S.E.
Andere beurzen
 00:00:00 08-05-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
18,47 CNY +10,01% Intraday-grafiek van Qingdao Vland Biotech INC. +33,17% +21,35%
07/05 Chinese aandelen dalen; Hongkongse aandelen dalen na 10 dagen winst RE
25/04 Qingdao Vland Biotech INC. meldt resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024 CI

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
China stocks edge down; HK shares fall after 10-day winning streak
Qingdao Vland Biotech INC. Reports Earnings Results for the First Quarter Ended March 31, 2024
Qingdao Vland Biotech INC. Reports Earnings Results for the Full Year Ended December 31, 2023
Qingdao Vland Biotech INC. Reports Earnings Results for the Nine Months Ended September 30, 2023
Qingdao Vland Biotech Forms Chinese JV With Germany’s Evonik
Qingdao Vland Biotech INC. Reports Earnings Results for the Half Year Ended June 30, 2023
Qingdao Vland Biotech INC. completed the acquisition of 51% stake in Qingdao RBT Biotechnology Co., Ltd. from Qingdao Jurun Management Consulting Partnership (Limited Partnership), Qingdao Gerunpu Management Consulting Partnership (Limited Partnership) and other individual shareholders.
Qingdao Vland Biotech Acquires 51% of Runbot Biotechnology for 91.8 Million Yuan
Qingdao Vland Biotech INC. signed a share transfer agreement to acquire a 51% stake in Qingdao RBT Biotechnology Co., Ltd. from Qingdao Jurun Management Consulting Partnership (Limited Partnership), Qingdao Gerunpu Management Consulting Partnership (Limited Partnership) and other individual shareholders for CNY 91.8 million.
Qingdao Vland Biotech INC. Reports Earnings Results for the First Quarter Ended March 31, 2023
Qingdao Vland Biotech INC. Reports Earnings Results for the Full Year Ended December 31, 2022
Qingdao Vland Biotech's Joint Venture to Invest Up to 400 Million Yuan for Probiotic Food Plant
Qingdao Vland Biotech INC. Reports Earnings Results for the Nine Months Ended September 30, 2022
Qingdao Vland Biotech INC. Reports Earnings Results for the Half Year Ended June 30, 2022
Qingdao Vland Biotech INC. Reports Earnings Results for the First Quarter Ended March 31, 2022
Qingdao Vland Biotech INC. Reports Earnings Results for the Full Year Ended December 31, 2021
Qingdao Vland Biotech INC. Reports Earnings Results for the Nine Months Ended September 30, 2021
Weifang Weizhilan Biological Technology Co., Ltd. announced that it expects to receive CNY 182.888 million in funding from Qingdao Vland Biotech INC., Archer Daniels Midland Singapore Pte Ltd.
Archer Daniels Midland : to Create Human Probiotics Joint Venture With Qingdao Vland Biotech Group
Qingdao Vland Biotech Inc. Reports Earnings Results for the Half Year Ended June 30, 2021
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers 603739
  4. Nieuws Qingdao Vland Biotech INC.
  5. Andere talen